Hillsdale Investment Management Inc. purchased a new position in shares of Enzo Biochem, Inc. (NYSE:ENZ) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 15,100 shares of the medical research company’s stock, valued at approximately $167,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Trexquant Investment LP purchased a new position in Enzo Biochem in the first quarter worth approximately $115,000. Legal & General Group Plc raised its position in Enzo Biochem by 10.6% in the second quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock valued at $119,000 after purchasing an additional 1,022 shares during the period. KCG Holdings Inc. purchased a new stake in Enzo Biochem in the first quarter valued at $141,000. Prudential Financial Inc. purchased a new stake in Enzo Biochem in the first quarter valued at $149,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Enzo Biochem in the 2nd quarter valued at $155,000. 62.70% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/03/hillsdale-investment-management-inc-purchases-new-holdings-in-enzo-biochem-inc-enz.html.

Enzo Biochem, Inc. (NYSE ENZ) opened at 10.44 on Tuesday. The firm’s 50-day moving average price is $10.94 and its 200-day moving average price is $10.05. The firm’s market capitalization is $485.95 million. Enzo Biochem, Inc. has a 1-year low of $4.88 and a 1-year high of $12.04.

A number of brokerages recently issued reports on ENZ. BidaskClub raised Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 19th. Zacks Investment Research lowered shares of Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, August 15th. Finally, TheStreet cut shares of Enzo Biochem from a “b” rating to a “c+” rating in a research report on Wednesday, September 27th.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Stock Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related stocks with our FREE daily email newsletter.